Biodexa Pharmaceuticals (NASDAQ:
BDRX) announced on April 2, 2026, a partnership with Syngene International to manufacture both the active pharmaceutical ingredient (API) and dosage form of MTX240 under GMP standards.
This is the second collaboration between Biodexa and Syngene, following Syngene's successful on-time and on-budget production of tolimidone dosage form.
Syngene designed the GMP manufacturing program within weeks after Biodexa licensed MTX240 from Otsuka in early February 2026.
MTX240 uses molecular glue technology to stabilize PDE3a and SLFN12 proteins in TKI-resistant GIST cells, triggering cell death via an alternative pathway.
Biodexa plans to file an IND and start a Phase 1b/2a clinical trial by year-end, including dose escalation and expansion phases for TKI-resistant GIST patients.